# Continuous Glucose Monitors for Weight Loss: What Stelo, Lingo, Dexcom, and FreeStyle Libre Actually Tell You > **Summary:** A continuous glucose monitor measures interstitial glucose every 1 to 5 minutes. In type 2 and type 1 diabetes it clearly improves outcomes and is standard of care. For weight loss in adults without diabetes the RCT signal is small but real — roughly 1 to 2 kg over 3 to 6 months when paired with behavioural coaching. Stelo (Dexcom, OTC 2024) and Lingo (Abbott, US launch 2024) made CGMs mainstream, and glucose spikes in non-diabetics are mostly normal physiology, not a weight-loss failure signal. > **Publisher:** WeightFAQ > **Author:** WeightFAQ Staff > **Published:** 2026-07-06 > **Updated:** 2026-07-06 > **Canonical URL:** https://weightfaq.com/weight-loss/continuous-glucose-monitors-for-weight-loss/ > **Content type:** Evergreen guide > **Tags:** continuous glucose monitor, CGM, Stelo, Lingo, Dexcom, FreeStyle Libre, metabolic health, glucose response > **Image:** https://weightfaq.com/_astro/continuous-glucose-monitors-for-weight-loss-hero.CBJlOJb7.webp — Unbranded round continuous glucose monitor sensor patch on a clean matte surface beside a smartphone showing a flat glucose trace, illustrating CGM use for weight loss and metabolic health. A continuous glucose monitor — **CGM** — is a small sensor worn on the upper arm or abdomen that measures **interstitial glucose** every 1 to 5 minutes for 10 to 15 days per sensor. In **type 1 diabetes** and **insulin-treated type 2 diabetes**, CGM is standard of care and clearly improves outcomes (**Beck 2017 DIAMOND**, *JAMA*; **Martens 2021 MOBILE**, *JAMA*; **Aleppo 2017 REPLACE-BG**). In **adults without diabetes**, the picture is very different — the randomised evidence for CGM-guided weight loss is modest (roughly 1 to 2 kg over 3 to 6 months when paired with behavioural coaching), and glucose spikes to 140 to 180 mg/dL after a normal meal are usually **normal physiology, not a weight-loss failure signal**. The 2024 launch of over-the-counter CGMs — **Stelo** (Dexcom, FDA-cleared 2024-03) and **Lingo** (Abbott, US launch 2024-09) — moved CGMs from a diabetes tool into a mainstream wellness and weight-loss category. This guide covers what a CGM actually measures, what the RCT evidence supports, when a CGM is genuinely helpful (T2D on insulin, T1D, reactive-hypoglycaemia workup, post-bariatric dumping-syndrome characterisation), when it is mostly noise (chasing every spike in a non-diabetic adult), and how to decide whether Stelo, Lingo, Dexcom G7, or FreeStyle Libre 3 is the right choice. ## Quick stats - **What a CGM measures**: interstitial glucose, every 1 to 5 minutes, with a 5 to 15 minute lag vs blood. - **Sensor life**: **10 days** (Dexcom G7, Stelo), **14 days** (FreeStyle Libre 3), **14 days** (Lingo). - **OTC status**: **Stelo** cleared 2024-03 (Dexcom); **Lingo** launched 2024-09 (Abbott). **Dexcom G7** and **FreeStyle Libre 3** are prescription CGMs. - **RCT weight-loss signal in non-diabetic adults**: roughly **1 to 2 kg** at 3 to 6 months paired with coaching (**Cohen 2019**; **Chow 2023**; **Ehrhardt 2019**). - **Non-diabetic post-meal glucose**: routine excursions to **140 to 180 mg/dL** and back to baseline within 90 to 180 minutes are normal (**Zeevi 2015**, *Cell*). - **Time-in-range target in diabetes**: **>70 percent** of readings between 70 and 180 mg/dL (**Battelino 2019 consensus**, *Diabetes Care*). - **CGM accuracy** (MARD): roughly **8 to 10 percent** for modern sensors versus a lab reference (**Kovatchev 2019**). - **CGM adherence signal**: about **60 percent** of non-diabetic wearers stop within 6 months (**Klonoff 2023 International Consensus**). - **911 red flags**: persistent CGM readings below **54 mg/dL** in a non-diabetic adult (workup for reactive hypoglycaemia, dumping, or insulinoma); fainting; sensor allergic reaction with airway or breathing symptoms. ## CGM device primer The category has separated into two tracks in 2026: the prescription CGMs originally developed for diabetes, and the OTC wellness CGMs launched in 2024 for non-diabetic adults. All four leading devices use the same underlying interstitial-glucose sensor chemistry; the differentiators are sensor life, prescription status, cost, and app / coaching layer. | Device | Sensor life | Rx status | Cost per month (US, 2026) | Target user | | --- | --- | --- | --- | --- | | **Dexcom G7** | 10 days | Prescription | ~$150 with insurance, $300+ cash | T1D, insulin-treated T2D, non-insulin T2D per Medicare rules | | **Stelo** (Dexcom OTC) | 15 days | **OTC** (cleared 2024-03) | ~$89 per month, ~$99 single-month | Non-diabetic adults, prediabetes, wellness | | **FreeStyle Libre 3** | 14 days | Prescription | ~$75 with insurance, ~$140 cash | T1D, T2D on insulin, T2D per Medicare rules | | **Lingo** (Abbott OTC) | 14 days | **OTC** (US launch 2024-09) | ~$89 per month | Non-diabetic adults, behaviour-change wellness | | **Nutrisense-style analytics** | Dexcom / Libre sensor + software | Requires Rx or OTC sensor | $200–$400 per month bundled | Data-driven learners who want dietitian coaching layer | ## What a CGM actually tells you A CGM does not measure one thing well — it measures four things, each with a different clinical weight and each easy to misinterpret without the diabetes context that framed how the readings are interpreted. ### 1. Time-in-range (TIR): 70 to 180 mg/dL The **Battelino 2019** International Consensus on Time in Range (*Diabetes Care*) codified TIR as the primary CGM metric in diabetes: the percentage of readings between 70 and 180 mg/dL over a 14-day window. The consensus targets are **>70 percent time-in-range** for most non-pregnant adults with diabetes and **<4 percent time-below-range**. TIR translates roughly to A1c — 70 percent TIR corresponds to an A1c near 7.0 percent — but it captures glycaemic variability and hypoglycaemia that A1c hides. In a **non-diabetic wearer**, TIR is nearly always 95 percent or higher; the metric is not a meaningful weight-loss lever in that population. ### 2. Glycaemic variability Variability — how much glucose bounces around a mean — is measured by the **coefficient of variation (CV)** across all readings. In diabetes, **CV <36 percent** is the consensus target for stability (**Battelino 2019**). Elevated CV is a signal for pre-diabetes progression risk and, in symptomatic adults, for reactive hypoglycaemia. This is the CGM metric with the most non-diabetic informational value: a spiky, wide-variability trace can flag the meals or timing patterns that most disrupt glucose control, even in the absence of a diabetes diagnosis. ### 3. Post-prandial excursions The number most non-diabetic wearers focus on — how high glucose peaks after a meal — is also the most easily misinterpreted. **Zeevi 2015** (*Cell*) showed that the same food produces dramatically different post-prandial responses across individuals; there is no universal "bad" glucose response. In a healthy adult, post-prandial excursions to **140 to 180 mg/dL** returning to baseline within 90 to 180 minutes are normal. Sustained excursions above 200 mg/dL, delayed returns to baseline, or a rising **2-hour post-prandial glucose above 140 mg/dL** across multiple days warrant a prescriber conversation and a formal **OGTT** or **HbA1c** — not a smaller portion of oatmeal. ### 4. Interstitial lag and calibration CGMs measure glucose in **interstitial fluid** — the fluid between cells beneath the skin — not in blood. Interstitial glucose lags blood glucose by **5 to 15 minutes**, and the two can disagree by **15 to 20 percent**, especially during rapid glucose changes. This is not device failure. **Kovatchev 2019** and the FDA accuracy standard framework quantify the discrepancy as **MARD** (mean absolute relative difference) versus a lab reference; modern CGMs achieve MARD near 8 to 10 percent. On the **first day** of a new sensor and immediately after insertion, MARD is worst; by day 2 or 3 the reading stabilises. Understanding this artifact prevents the very common "the CGM is broken" moment when the number does not match a finger-stick. ## Time course — what to expect over the first year For a non-diabetic wearer using CGM as a behaviour-change tool, the arc is predictable: the first days are calibration and orientation, weeks 1 to 4 are where behaviour change happens, and month 6 is where most adults stop wearing. | Timepoint | What is happening | What to focus on | | --- | --- | --- | | **Days 0 to 3** | Sensor calibration, first-day artifact, unfamiliar readings | Do not draw conclusions; expect the reading to disagree with a finger-stick by 15 to 20% | | **Weeks 1 to 2** | First behavioural changes — meal-by-meal A/B testing, walk-after-meal experiments | Identify the two or three meals that produce the largest excursions and the effect of a 10 to 20 minute post-meal walk | | **Weeks 3 to 4** | Habit consolidation — the mealtime changes stick or they do not | Log what changed; document the successful swaps so they persist after you stop wearing | | **Month 3** | Typical RCT weight-loss signal — **~1 to 2 kg** in CGM + coaching arms (**Ehrhardt 2019**; **Chow 2023**) | Reassess whether continued wear is delivering additional insight or has become noise | | **Month 6** | Typical CGM-quit rate ~**60 percent** in non-diabetic wearers (**Klonoff 2023**) | Most learners have extracted the useful information by now — a scheduled break is reasonable | | **Month 12** | Sustained wearers show maintenance benefit; drop-outs revert to baseline habits without the feedback | Consider intermittent wear (2 to 4 weeks quarterly) rather than continuous — same signal, lower cost | ## The RCT evidence — what CGM does and does not do for weight The randomised evidence for CGM sits in two clearly separated populations. In **type 2 diabetes on insulin**, the CGM signal is large and consistent. In **non-diabetic adults using CGM for weight loss**, the signal is small — real, but small — and depends on the coaching layer wrapped around the sensor. **Beck 2017 DIAMOND** (*JAMA*) enrolled 158 adults with T2D on multiple daily insulin injections and reported a **0.3 percent additional A1c reduction** at 24 weeks in the CGM arm versus finger-stick monitoring, with a mean CGM-arm weight change of approximately 0.5 kg. **Martens 2021 MOBILE** (*JAMA*) enrolled 175 adults with T2D on basal insulin only and reported a **0.4 percent additional A1c reduction** at 8 months in the CGM arm. **Aleppo 2017 REPLACE-BG** confirmed that CGM can replace routine finger-stick monitoring in adults with T1D — a category shift, not a modest tweak. These are the trials that made CGM standard of care in insulin-treated diabetes. **Cohen 2019** and **Chow 2023** are the closest RCTs to the "non-diabetic weight loss" question. Cohen enrolled non-diabetic adults with obesity and reported a modest weight-loss advantage in the CGM + coaching arm versus coaching alone at 12 weeks. Chow reported similar results at 24 weeks — roughly **1 to 2 kg additional weight loss** in CGM arms — with the caveat that the effect was concentrated in adults who used the CGM data to change specific behaviours (post-meal walks, timing of the largest meal, portion downsizing). The weight loss was mediated by behaviour change, not by the sensor itself. **Ehrhardt 2019** (prediabetes) reported that CGM users made more behavioural adjustments than controls and had a modest metabolic benefit at 12 weeks; the study was not powered to detect a large weight-loss effect. **Zeevi 2015** (*Cell*) is the personalised-nutrition anchor: identical meals produce very different post-prandial glucose responses across individuals, and there is no universal "healthy glucose response" curve. **Klonoff 2023 International Consensus on Use of CGM** codified the current framework: CGM is standard of care in insulin-treated diabetes, useful in non-insulin T2D on multi-drug therapy per Medicare 2023 rules, useful diagnostically in reactive hypoglycaemia and dumping syndrome, and a **modest behaviour-change tool** for non-diabetic wellness. The **ADA 2024 Standards of Care Section 7** recommend CGM for T1D, T2D on multiple daily insulin injections or continuous subcutaneous insulin infusion, and increasingly for T2D on basal insulin — but not as a stand-alone weight-loss intervention in adults without diabetes. ## CGM vs other measurement tools for weight loss | Tool | What it measures | Approximate cost | Evidence for weight loss | Actionability | | --- | --- | --- | --- | --- | | **CGM (Dexcom G7, Libre 3, Stelo, Lingo)** | Interstitial glucose every 1–5 minutes | $75–$300 per month | Modest in non-diabetes; strong in insulin-treated T2D | High for T1D, T2D on insulin; moderate for behaviour-change wellness | | **Finger-stick blood glucose meter** | Capillary blood glucose at one moment | $10–$40 device + $0.20–$1 per strip | Weak stand-alone; used with insulin dose | Situational — a single number | | **Food journal (paper or app)** | What and how much you ate | Free–$20 per year | **Moderate** — the strongest lifestyle intervention (**Hollis 2008**) | High — direct behaviour change lever | | **Macro-tracking app** (MyFitnessPal, Cronometer) | Calories, protein, carbs, fats | Free–$100 per year | Moderate — depends on adherence | High for portion and protein targeting | | **Personalised nutrition analysis** (Zeevi-style) | Individual glucose response to specific foods | $200–$500 for a testing window | Emerging — small trials only | Moderate — informs meal choices | | **OGTT (oral glucose tolerance test)** | Blood glucose 2 hours after 75 g glucose | $30–$100 for the lab | Diagnostic, not treatment | Diagnostic — used to identify prediabetes / T2D | | **HbA1c** | 3-month average blood glucose | $20–$50 for the lab | Diagnostic and monitoring | Diagnostic — used to identify prediabetes / T2D | ## 5-step "should I actually get a CGM?" protocol The right answer is not the same for every reader. The five-question flow below reflects how endocrinologists and diabetes educators triage CGM decisions in 2026. ### Step 1 — Type 1 or insulin-treated type 2 diabetes **Yes — a prescription CGM is standard of care.** Dexcom G7 and FreeStyle Libre 3 both have clear insulin-dosing accuracy and both are covered by Medicare and most commercial insurance for this indication. See our companion coverage of [insulin therapy and weight in type 2 diabetes](https://weightfaq.com/weight-loss/insulin-therapy-and-weight-in-type-2-diabetes/) and [type 1 diabetes and weight loss](https://weightfaq.com/weight-loss/type-1-diabetes-and-weight-loss/) for how CGM integrates with the dosing algorithm. ### Step 2 — Non-insulin type 2 diabetes or prediabetes **Discuss with the prescriber.** The **DIAMOND**, **MOBILE**, and **Ehrhardt 2019** data support CGM value in adults on metformin and GLP-1 or SGLT2 layered therapy, and Medicare 2023 expanded CGM coverage to include non-insulin T2D adults with problematic hypoglycaemia. **Isaacs 2020** made the broader case for CGM in T2D not on insulin. See [prediabetes and weight loss](https://weightfaq.com/weight-loss/prediabetes-and-weight-loss/), [metformin and weight](https://weightfaq.com/weight-loss/metformin-and-weight/), and [insulin resistance and weight loss](https://weightfaq.com/weight-loss/insulin-resistance-weight-loss/) for the surrounding treatment picture. ### Step 3 — Reactive hypoglycaemia workup or post-bariatric dumping syndrome **Yes for two weeks — diagnostic, not chronic use.** CGM is the modern way to characterise both patterns (**Craig 2021** documented CGM use in post-bariatric dumping). The two-week window captures the trigger meals and the pattern of the drop; beyond that, the CGM is not additive to a food-and-symptom diary. See [hypoglycemia and weight loss](https://weightfaq.com/weight-loss/hypoglycemia-and-weight-loss/) and [dumping syndrome after bariatric surgery](https://weightfaq.com/weight-loss/dumping-syndrome-after-bariatric-surgery/) for the workup framework. ### Step 4 — Non-diabetic weight loss **Yes if you are a data-driven learner** who will use the CGM to A/B-test meals for two to four weeks and then stop. **No if you will spend $200 per month for 12 months chasing every spike** — the RCT signal is 1 to 2 kg (**Chow 2023**), the adherence curve drops to ~40 percent by month 6 (**Klonoff 2023**), and the cost math does not favour chronic wear. The honest use case is a short educational window, not a chronic gadget. ### Step 5 — How to actually use it Take a **before snapshot** of your typical week — the meals, the walks, the timing. Wear the sensor for **two to four weeks**. Pair Stelo or Lingo with the built-in app coaching layer (this is where the behaviour-change value sits). Test **specific hypotheses**: does a 10-minute walk after breakfast flatten the excursion? Does eating protein first flatten the excursion? Do not chase every spike to zero — the goal is not a flat line, it is a mental model of how your body responds to your typical meals so the learning persists after you stop wearing. ## Special situations ### T2D on insulin CGM is standard of care and the strongest evidence base in the CGM literature (**Beck 2017 DIAMOND**; **Martens 2021 MOBILE**; **Aleppo 2017 REPLACE-BG**; **ADA 2024 Standards of Care Section 7**). Use CGM to titrate basal insulin to fasting glucose targets, to detect nocturnal hypoglycaemia, and to identify the post-prandial meals that most disrupt time-in-range. See [insulin therapy and weight in type 2 diabetes](https://weightfaq.com/weight-loss/insulin-therapy-and-weight-in-type-2-diabetes/) for the layering strategy. ### T2D on metformin ± GLP-1 CGM catches nocturnal drops and post-prandial excursions that fasting glucose alone misses. In an adult on metformin plus a GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide, dulaglutide), a two-week CGM window can identify whether A1c drift is driven by fasting glucose (dose-adjust the metformin or add basal) or post-prandial spikes (the GLP-1 will typically flatten these; if it does not, portion size is usually the issue). See [metformin and weight](https://weightfaq.com/weight-loss/metformin-and-weight/) and [GLP-1 weight loss overview](https://weightfaq.com/weight-loss/glp-1-weight-loss-overview/). ### Reactive hypoglycaemia and post-prandial dizziness CGM is diagnostic. A two-week trace that shows repeated drops below 70 mg/dL 2 to 4 hours after high-carbohydrate meals — coupled with symptoms in the food-and-symptom diary — is characteristic of reactive hypoglycaemia. See [hypoglycemia and weight loss](https://weightfaq.com/weight-loss/hypoglycemia-and-weight-loss/). ### Dumping syndrome after bariatric surgery CGM has become the standard modern way to characterise both early dumping (rapid post-meal excursion) and late dumping (reactive hypoglycaemia 1 to 3 hours after a high-carbohydrate meal), replacing older provocative-testing protocols in most centres (**Craig 2021**). See [dumping syndrome after bariatric surgery](https://weightfaq.com/weight-loss/dumping-syndrome-after-bariatric-surgery/). ### Non-diabetic weight loss The signal is modest. Behaviour change — not glucose per se — is the mechanism. Use CGM as a two-to-four-week educational window, not a chronic surveillance tool. Expect roughly 1 to 2 kg additional weight loss at 3 to 6 months over coaching alone (**Chow 2023**), and expect diminishing returns beyond one or two months. ### PCOS and insulin resistance CGM can visualise the insulin-resistance response pattern — a flatter but longer excursion, a delayed return to baseline, and higher fasting glucose. This is often more motivating than a single fasting glucose number in adults building the case for metformin, a GLP-1, or dedicated weight-loss lifestyle work. See [PCOS and weight loss](https://weightfaq.com/weight-loss/pcos-and-weight-loss/) and [insulin resistance and weight loss](https://weightfaq.com/weight-loss/insulin-resistance-weight-loss/). ### Endurance athletes and low-carb dieters Expect **flat glucose lines and low averages**. This is not a problem or a "broken metabolism." Ultra-endurance athletes and adults on ketogenic or low-carb regimens routinely show 24-hour CGM averages in the 80s and post-meal peaks that barely reach 130 mg/dL. Interpreting these traces against a diabetes-population framework is a common source of unnecessary alarm. ### Pregnancy and gestational diabetes CGM use in gestational diabetes and pre-existing T2D during pregnancy is increasing but not yet uniformly covered. The **ADA 2024** framework recognises CGM as useful for adults with gestational diabetes requiring insulin. Stelo and Lingo are not indicated for pregnancy management — pregnancy CGM use should be under a prescriber's care with a prescription device. See [gestational diabetes and weight loss](https://weightfaq.com/weight-loss/gestational-diabetes-and-weight-loss/). ## Myths and red flags - **"Every glucose spike is fat storage"** — no. In non-diabetic adults, post-meal excursions to 140 to 180 mg/dL and back to baseline are normal physiology. There is no evidence that flattening these excursions accelerates weight loss. - **"A CGM can replace an A1c"** — no. CGM captures time-in-range and variability; A1c captures the 3-month glycaemic average. They measure related but distinct things, and both are used together in the diabetes clinic. - **"Higher-carb meals are always the problem"** — no. **Zeevi 2015** (*Cell*) showed the same meal produces very different responses across individuals; there is no universal problematic food. - **"CGM readings are as accurate as a lab draw"** — no. MARD is roughly 8 to 10 percent for modern CGMs, and interstitial-lag differences of 15 to 20 percent versus a finger-stick are normal during rapid glucose changes (**Kovatchev 2019**). - **Fainting, sensor allergic reaction with airway or breathing symptoms** — call **911**. - **Persistent CGM readings below 54 mg/dL in a non-diabetic adult** — see a physician. The differential includes reactive hypoglycaemia, post-bariatric dumping syndrome, and rarely insulinoma; a targeted endocrinology workup is appropriate. ## Bottom line A continuous glucose monitor measures interstitial glucose every 1 to 5 minutes. In **type 1 diabetes and insulin-treated type 2 diabetes**, CGM is standard of care and clearly improves outcomes. In **non-insulin T2D on multi-drug therapy** and in **prediabetes with behavioural coaching**, CGM adds modest value. For **reactive-hypoglycaemia workup** and **post-bariatric dumping-syndrome characterisation**, a two-week CGM is diagnostic. For **non-diabetic adults using CGM for weight loss**, the RCT signal is roughly **1 to 2 kg** over 3 to 6 months, the effect is mediated by behaviour change and not by the sensor, and the practical use is a **two-to-four-week educational window** — not chronic surveillance. **Stelo** and **Lingo** made CGMs an OTC wellness category in 2024; both are reasonable short-term experiments at $89 to $99 per month for a data-driven learner, and both are the wrong purchase for someone who will chase every normal post-meal excursion for a year. ## How this connects to the rest of the site For the diabetes context, see [diabetes and weight loss](https://weightfaq.com/weight-loss/diabetes-and-weight-loss/), [prediabetes and weight loss](https://weightfaq.com/weight-loss/prediabetes-and-weight-loss/), [type 1 diabetes and weight loss](https://weightfaq.com/weight-loss/type-1-diabetes-and-weight-loss/), [gestational diabetes and weight loss](https://weightfaq.com/weight-loss/gestational-diabetes-and-weight-loss/), and [insulin therapy and weight in type 2 diabetes](https://weightfaq.com/weight-loss/insulin-therapy-and-weight-in-type-2-diabetes/). For the glucose-drop workup, see [hypoglycemia and weight loss](https://weightfaq.com/weight-loss/hypoglycemia-and-weight-loss/) and [dumping syndrome after bariatric surgery](https://weightfaq.com/weight-loss/dumping-syndrome-after-bariatric-surgery/). For the underlying physiology and the surrounding drug classes, see [insulin resistance and weight loss](https://weightfaq.com/weight-loss/insulin-resistance-weight-loss/), [metformin and weight](https://weightfaq.com/weight-loss/metformin-and-weight/), [SGLT2 inhibitors and weight](https://weightfaq.com/weight-loss/sglt2-inhibitors-and-weight/), and [PCOS and weight loss](https://weightfaq.com/weight-loss/pcos-and-weight-loss/).

Sources